Joseph Monahan - May 5, 2021 Form 3 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Scientific Officer
Signature
/s/ Mark Ballantyne, as Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
May 5, 2021
Transactions value $
$0
Form type
3
Date filed
5/17/2021, 06:06 PM
Next filing
Jun 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACRS Common Stock 57.1K May 5, 2021 Direct
holding ACRS Common Stock 193 May 5, 2021 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACRS Employee Stock Option (Right to Buy) May 5, 2021 Common Stock 56K $25.80 Direct F1
holding ACRS Employee Stock Option (Right to Buy) May 5, 2021 Common Stock 14.7K $22.09 Direct F2
holding ACRS Restricted Stock Units May 5, 2021 Common Stock 2.33K Direct F3, F4
holding ACRS Restricted Stock Units May 5, 2021 Common Stock 1.05K Direct F4, F5
holding ACRS Restricted Stock Units May 5, 2021 Common Stock 27.5K Direct F4, F6
holding ACRS Restricted Stock Units May 5, 2021 Common Stock 50K Direct F4, F7
holding ACRS Restricted Stock Units May 5, 2021 Common Stock 37.5K Direct F4, F8
holding ACRS Restricted Stock Units May 5, 2021 Common Stock 200K Direct F4, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a period of four years. 75% of the shares are currently vested with the remaining 25% vesting on September 1, 2021, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
F2 The option vests over a period of four years. 75% of the shares are currently vested with the remaining 25% vesting on February 1, 2022, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
F3 The shares underlying these restricted stock units vest on September 1, 2021, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F4 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F5 The shares underlying these restricted stock units vest on February 1, 2022, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F6 The shares underlying these restricted stock units vest over a period of two years, with 50% vesting on March 1, 2022 and 50% vesting on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F7 The shares underlying these restricted stock units vest on June 1, 2021, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F8 The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 2, 2022, March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F9 The shares underlying these restricted stock units vest over a period of four years, with 25% vesting on the first, second, third and fourth anniversaries of the date of grant, beginning on March 1, 2022, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney